
## Mark Yates

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/214895/publications.pdf Version: 2024-02-01



Μλρκ Υλτές

#	Article	IF	CITATIONS
1	Venous Thromboembolism Risk With JAK Inhibitors: A Metaâ€Analysis. Arthritis and Rheumatology, 2021, 73, 779-788.	2.9	86
2	The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. Pharmacological Research, 2019, 147, 104392.	3.1	62
3	The safety of JAK-1 inhibitors. Rheumatology, 2021, 60, ii24-ii30.	0.9	59
4	Superresolution imaging of the cytoplasmic phosphatase PTPN22 links integrin-mediated T cell adhesion with autoimmunity. Science Signaling, 2016, 9, ra99.	1.6	37
5	IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. Journal of Infection, 2021, 82, 178-185.	1.7	37
6	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology, 2022, 61, 1760-1768.	0.9	37
7	Riskâ€mitigating behaviours in people with inflammatory skin and joint disease during the COVIDâ€19 pandemic differ by treatment type: a crossâ€sectional patient survey*. British Journal of Dermatology, 2021, 185, 80-90.	1.4	26
8	Placebo Response in Rheumatoid Arthritis Clinical Trials. Journal of Rheumatology, 2020, 47, 28-34.	1.0	24
9	Rising Incidence of Acute Hospital Admissions due to Gout. Journal of Rheumatology, 2020, 47, 619-623.	1.0	21
10	Describing the burden of the COVIDâ€19 pandemic in people with psoriasis: findings from a global crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	1.3	18
11	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1800-1809.	2.9	18
12	Defining and measuring imaging appropriateness in low back pain studies: a scoping review. European Spine Journal, 2020, 29, 519-529.	1.0	14
13	Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register. Rheumatology, 2020, 59, 2563-2571.	0.9	14
14	Data quality predicts care quality: findings from a national clinical audit. Arthritis Research and Therapy, 2020, 22, 87.	1.6	11
15	The impact of COVID-19 on clinical care, self-management and mental health of patients with inflammatory arthritis. Rheumatology Advances in Practice, 2022, 6, rkab095.	0.3	10
16	Variation and implications of treatment decisions in early rheumatoid arthritis: results from a nationwide cohort study. Rheumatology, 2020, 59, 2035-2042.	0.9	8
17	Disease activity and its predictors in early inflammatory arthritis: findings from a national cohort. Rheumatology, 2021, 60, 4811-4820.	0.9	8
18	A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report. Wellcome Open Research, 0, 6, 360.	0.9	8

MARK YATES

#	Article	IF	CITATIONS
19	Hydroxychloroquine use: the potential impact of new ocular screening guidelines. Eye, 2018, 32, 161-162.	1.1	7
20	Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit. Rheumatology, 2022, 61, 734-742.	0.9	6
21	A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis. Rheumatology, 2021, 60, 4450-4462.	0.9	6
22	Systematic Review and Metaanalysis of the Reproducibility of Patient Self-reported Joint Counts in Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, jrheum.201439.	1.0	5
23	The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know. Journal of Rheumatology, 2021, 48, 1201-1204.	1.0	5
24	Exploring the macro-level, meso-level and micro-level barriers and facilitators to the provision of good quality early inflammatory arthritis (EIA) care in England and Wales. RMD Open, 2021, 7, e001616.	1.8	4
25	The use of real-world data to address questions of patient safety. Rheumatology, 2020, 59, 26-30.	0.9	3
26	NEIAA: driving EIA service quality in a shifting clinical landscape. Rheumatology, 2020, 59, 3127-3128.	0.9	3
27	230â€ $f$ Liver function abnormalities on conventional DMARDs: results from a contemporary cohort. Rheumatology, 2018, 57, .	0.9	1
28	Centre effects and case-mix in early rheumatoid arthritis observational cohorts: a narrative review. Rheumatology, 2019, 58, 1991-1999.	0.9	1
29	SAT0676â€(SERONEGATIVE) males show better eular treatment response than females in newly diagnosed rheumatoid arthritis (RA). , 2017, , .		0
30	SAT0699â€Rapid assessment predicts disease activity improvement in newly diagnosed rheumatoid arthritis (RA). , 2017, , .		0
31	i027 National arthritis audit it portal demonstration. Rheumatology, 2018, 57, .	0.9	0
32	O04 Return of the king: rising incidence of gout in England 2006-2017 (Young investigator award) Tj ETQq0	0 0 rgBT /	Overlock 10 T
33	AB1280â€Predicting work disability, pension claim, absenteeism and presenteeism in ra patients. , 2018, , .		0
34	O06 Hydroxychloroquine use, risk of retinal toxicity, and potential impact of screening in a large tertiary centre. Rheumatology, 2018, 57, .	0.9	0
35	229â $\in f$ The impact of the EIA clinic on early RA care. Rheumatology, 2018, 57, .	0.9	0
36	Better is possible. Rheumatology, 2019, 58, 741-742.	0.9	0

#	Article	IF	CITATIONS
37	17. Tick-borne relapsing fever: a fever syndrome mimic. Rheumatology Advances in Practice, 2019, 3, .	0.3	0
38	209 Quantifying care variation: the keystone of national quality improvement. Rheumatology, 2019, 58, .	0.9	0
39	AB1255â€A review of case-mix and centre effect adjustment in early rheumatoid arthritis cohorts. , 2018, ,		0